| Dr Michael L Hinni, MD | |
|
5779 E Mayo Blvd, Phoenix, AZ 85054-4502 | |
| (480) 301-8000 | |
| Not Available |
| Full Name | Dr Michael L Hinni |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 36 Years |
| Location | 5779 E Mayo Blvd, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073598736 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 21929 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic - Arizona | 7012829930 | 1395 |
News Archive
In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.
Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.
In a new study published in American Journal of Human Genetics, a team of researchers led by Charis Eng, M.D., Ph.D., Chair of Cleveland Clinic's Genomic Medicine Institute, identified a metabolite that may predict whether individuals with PTEN mutations will develop cancer or autism spectrum disorder.
To regenerate dental pulp tissue after emptying of a tooth's root canals researchers compared the effectiveness of 3D scaffolds made of natural or customized synthetic materials containing pulpal stem cells and dentin-derived growth factors.
A team of researchers at the Institute of Oncology Research has identified a new class of regulatory RNAs, which are able to act as molecular switches and can contribute in controlling the genetic evolution processes that are responsible for some cancer pathologies.
› Verified 2 days ago
| Entity Name | Mayo Clinic Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558332494 PECOS PAC ID: 7012829930 Enrollment ID: O20031105000782 |
News Archive
In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.
Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.
In a new study published in American Journal of Human Genetics, a team of researchers led by Charis Eng, M.D., Ph.D., Chair of Cleveland Clinic's Genomic Medicine Institute, identified a metabolite that may predict whether individuals with PTEN mutations will develop cancer or autism spectrum disorder.
To regenerate dental pulp tissue after emptying of a tooth's root canals researchers compared the effectiveness of 3D scaffolds made of natural or customized synthetic materials containing pulpal stem cells and dentin-derived growth factors.
A team of researchers at the Institute of Oncology Research has identified a new class of regulatory RNAs, which are able to act as molecular switches and can contribute in controlling the genetic evolution processes that are responsible for some cancer pathologies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael L Hinni, MD 5779 E Mayo Blvd, Phoenix, AZ 85054-4502 Ph: (480) 301-8000 | Dr Michael L Hinni, MD 5779 E Mayo Blvd, Phoenix, AZ 85054-4502 Ph: (480) 301-8000 |
News Archive
In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.
Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.
In a new study published in American Journal of Human Genetics, a team of researchers led by Charis Eng, M.D., Ph.D., Chair of Cleveland Clinic's Genomic Medicine Institute, identified a metabolite that may predict whether individuals with PTEN mutations will develop cancer or autism spectrum disorder.
To regenerate dental pulp tissue after emptying of a tooth's root canals researchers compared the effectiveness of 3D scaffolds made of natural or customized synthetic materials containing pulpal stem cells and dentin-derived growth factors.
A team of researchers at the Institute of Oncology Research has identified a new class of regulatory RNAs, which are able to act as molecular switches and can contribute in controlling the genetic evolution processes that are responsible for some cancer pathologies.
› Verified 2 days ago
Dr. Shawn Michael Stevens, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave # 330, Phoenix, AZ 85013 Phone: 602-406-8811 Fax: 602-406-8810 | |
Charles R Orozco, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4250 E Camelback, Suite K-250, Phoenix, AZ 85018 Phone: 602-253-9026 Fax: 602-252-6391 | |
John David Macias, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1515 N 9th St, Suite B, Phoenix, AZ 85006 Phone: 602-257-4228 Fax: 602-252-6416 | |
Randy Oppenheimer, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 2601 E Roosevelt St, Department Of Surgery, Phoenix, AZ 85008 Phone: 602-344-5608 Fax: 602-344-1299 | |
Austin N Dehart, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1920 E Cambridge Ave Ste 201, Phoenix, AZ 85006 Phone: 602-933-3277 Fax: 602-933-4326 | |
Griffin Santarelli, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave # 330, Phoenix, AZ 85013 Phone: 602-406-8811 Fax: 602-406-8810 |